Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.

Antiviral research - 1 Jun 2008

Bartonová Vanda, Král Vlastimil, Sieglová Irena, Brynda Jirí, Fábry Milan, Horejsí Magdalena, Kozísek Milan, Sasková Klára Grantz, Konvalinka Jan, Sedlácek Juraj, Rezácová Pavlína

Abstract excerpt

The monoclonal antibodies 1696 and F11.2.32 strongly inhibit the activity of wild-type HIV-1 protease (PR) by binding to epitopes at the enzyme N-terminus (residues 1-6) and flap residues 36-46, respectively. Here we demonstrate that these antibodies are also potent inhibitors of PR variants resistant to active-site inhibitors used as anti-AIDS drugs. Our in vitro experiments revealed that the inhibitory potency...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dimerization

Share to Drug Resistance, Viral

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Immunoglobulin Fragments

Source

Identifiers

PMID: 18329737
DOI: 10.1016/j.antiviral.2008.01.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.PMID 18329737Read ↗

A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing AntibodiesSemantic proximity Read ↗

Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations.Semantic proximity Read ↗

Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.Semantic proximity Read ↗

Type-Specific Epitopes Targeted by Monoclonal Antibodies with Exceptionally Potent Neutralizing Activities for Selected Strains of Human Immunodeficiency Virus Type 1 Map to a Common Region of the V2 Domain of gp120 and Differ Only at Single Positions from the Clade B Consensus SequenceSemantic proximity Read ↗

Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development.Semantic proximity Read ↗

Dimeric 2G12 as a Potent Protection against HIV-1Semantic proximity Read ↗

Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.Semantic proximity Read ↗

A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity.Semantic proximity Read ↗

HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.Semantic proximity Read ↗

Monoclonal and polyclonal antibodies: reagents for studying HIV-1 proteinase variants.Semantic proximity Read ↗

F99 is critical for dimerization and activation of South African HIV-1 subtype C protease.Semantic proximity Read ↗

Conformational asymmetry of human immunodeficiency virus-1 protease flaps increases along the darunavir drug resistance pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.